Actively Recruiting
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
Led by Dianthus Therapeutics · Updated on 2026-04-30
36
Participants Needed
26
Research Sites
184 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of Claseprubart (DNTH103) in participants with multifocal motor neuropathy (MMN).
CONDITIONS
Official Title
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must have given written informed consent before any study-related activities are carried out
- Adult males and females, 18 to 75 years of age (inclusive)
- Weight range between 40 to 120 kilograms
- Confirmed diagnosis of definite or probable MMN
- Evidence of responsiveness to Ig treatment and receiving a stable Ig regimen
- Documented vaccinations against encapsulated bacteria as required locally
- Female participants must be of nonchildbearing potential or agree to use highly effective contraception if of childbearing potential
- Male participants must agree not to donate sperm and use acceptable contraception or be surgically sterile for at least 90 days before screening
You will not qualify if you...
- History or presence of significant medical or surgical conditions including acute illness or major surgery that could impact efficacy assessments
- Conditions interfering with outcome assessments such as severe diabetic neuropathy
- Current or previous use of rituximab, cyclophosphamide, mycophenolate mofetil, azathioprine, or cyclosporine within 6 months prior to randomization
- Current or previous use of complement inhibitors including in clinical trials
- Prior history of N. meningitidis infection
- Diagnosis of autoimmune disorders other than MMN
- Positive tests for active HIV-1, HIV-2, hepatitis B surface antigen, or hepatitis C virus antibodies during screening
- History of active malignancy within 5 years prior to screening except certain treated skin and cervical cancers or low-grade prostate adenocarcinoma under observation
- Participation in another investigational drug study within 90 days or 5 half-lives before randomization
- Any other overlapping condition or mental illness that could affect study assessments or participant compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 26 locations
1
Clinical Study Site
Scottsdale, Arizona, United States, 85251
Actively Recruiting
2
Clinical Study Site
Los Angeles, California, United States, 90048
Actively Recruiting
3
Clinical Study Site
Bradenton, Florida, United States, 34205
Actively Recruiting
4
Clinical Study Site
Tampa, Florida, United States, 33620
Actively Recruiting
5
Clinical Study Site
Honolulu, Hawaii, United States, 96817
Actively Recruiting
6
Clinical Study Site
Kansas City, Kansas, United States, 66103
Actively Recruiting
7
Clinical Study Site
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
8
Clinical Study Site
Cincinnati, Ohio, United States, 45219
Actively Recruiting
9
Clinical Study Site
Columbus, Ohio, United States, 43210
Actively Recruiting
10
Clinical Study Site
Houston, Texas, United States, 77030
Actively Recruiting
11
Clinical Study Site
Aarhus, Denmark, 8200
Actively Recruiting
12
Clinical Study Site
Copenhagen, Denmark, 1172
Actively Recruiting
13
Clinical Study Site
Marseille, France, 13005
Actively Recruiting
14
Clinical Study Site
Paris, France, 94000
Actively Recruiting
15
Clinical Study Site
Rome, Italy, 00189
Actively Recruiting
16
Clinical Study Site
Amsterdam, Netherlands, 1105
Actively Recruiting
17
Clinical Study Site
Utrecht, Netherlands
Actively Recruiting
18
Clinical Study Site
Skopje, North Macedonia
Actively Recruiting
19
Clinical Study Site
Bydgoszcz, Poland, 85-090
Actively Recruiting
20
Clinical Study Site
Katowice, Poland, 40-689
Actively Recruiting
21
Clinical Study Site
Krakow, Poland, 30-688
Actively Recruiting
22
Clinical Study Site
Krakow, Poland, 31-202
Actively Recruiting
23
Clinical Study Site
Belgrade, Serbia, 11000
Actively Recruiting
24
Clinical Study Site
Barcelona, Spain, 08035
Actively Recruiting
25
Clinical Study Site
London, England, United Kingdom
Actively Recruiting
26
Clinical Study Site
Oxford, England, United Kingdom
Actively Recruiting
Research Team
D
Dianthus Clinical Contact Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here